Browse by ▼

Sanofi (ADR)

  • New Sleeping Aid Could Be An Awakening for Merck

    By Diane Alter - May 23, 2013 | Tickers: JNJ, MRK, SNY

    Sleep or lack thereof, is a major problem for millions of individuals.

    A recent review published online in the journal The Lancet found nearly a quarter of all adults are unhappy with their sleep patterns. Meanwhile, some 10% meet the criteria for full-fledged insomnia.

    “Insomnia has traditionally been trivialized,” paper co-author Charles Morin, Ph.D., a sleep researcher and professor at the Universite Laval in Quesbe Citry told the Huffington more »

  • Catalyst Pharmaceuticals Successfully Repositions In Hot Orphan Drug Space

    By Michael Anderson - May 23, 2013 | Tickers: ALXN, BMRN, CPRX, PFE, SNY

    I was surprised to see Catalyst Pharmaceutical Partners, (NASDAQ: CPRX) Inc. break out to the upside following the announcement last November of disappointing results from the latest clinical trial of CPP-109 for cocaine addiction. After forming a solid base around $.50 for the past three months, Catalyst spiked to $1.06 and is now consolidating its' gain.  Technically, Catalyst looks like it is getting ready for another big advance.

    I more »

  • Too Many Questions Make This Thursday Mover a Sell

    By Brian Nichols - May 19, 2013 | Tickers: ACAD, AEGR, SNY

    Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) rallied an incredible 31.37% on Thursday after a series of bullish notes that painted a clearer picture for its newly approved (rare-cholesterol disease) drug Juxtapid. While the company’s current market capitalization of $1.75 billion suggests that Aegerion has a potential blockbuster on its hand, the reality is not quite so bullish.

    What created the movement?

    Aegerion Pharmaceuticals had previously reported that more »

  • Good News For Health Care Stocks Part 3

    By Reuben Brewer - May 17, 2013 | Tickers: NTRI, SNY, WTW

    A recent study showed that providing Medicaid coverage to lower-income residents of Oregon led to an increased use of health care services. While not at all a surprising outcome, taking that finding a step further can lead to some interesting investing ideas.

    The Oregon Study

    The New England Journal of Medicine recently released the results of the Oregon Study. That research tracked Oregon's test of randomly assigning lower-income adults more »

  • 3 Drug Catalysts to Watch in 2013

    By Brandy Betz - May 9, 2013 | Tickers: MNKD, MRK, PFE, RIGL, SNY

    Pharmaceutical investors: start your engines! We’re into the second quarter of 2013 and some major catalysts lurk right around the corner.

    Merck (NYSE: MRK) has a Food and Drug Administration meeting for a potential first-in-class insomnia treatment. The drug offers a better safety profile than the currently available treatments. MannKind (NASDAQ: MNKD)  returns with additional trial data that has delayed its anticipated diabetes inhalant. And Rigel Pharmaceuticals (NASDAQ: RIGLmore »)

  • Double-Digit Returns from the Biotechnology Strategy

    By Jeff Stouffer - May 7, 2013 | Tickers: NPSP, REGN, SNY, XBI, THRX, VRTX

    Investments in biotechnology by the average investor tend to deliver hit or miss returns over time. Since inception, the SPDR S&P Biotech ETF (NYSEMKT: XBI) has delivered double-digit returns. This ETF holds 53 stocks and is focused on this industry. Created on Jan. 31, 2006, the one-year return is 33.76%, the three-year return is 23.57%, and the five-year return is 13.27%. Only the one-month and three-month more »

  • Trounce the Market With This Diabetes Care Company

    By Greg Williamson - April 28, 2013 | Tickers: BDX, LLY, NVO, SNY

    Diabetes currently affects an estimated 350 million people worldwide. This number is projected to grow to well over 500 million people by 2030.

    Diabetes is a very serious disease that results from high levels of glucose caused by the body not being able to effectively produce insulin (type 1 diabetes) or use insulin (type 2 diabetes). Diabetes is a leading cause of a wide variety of complications including kidney failure more »

  • Checking in on This Ex-Lehman Hedge Fund’s Favorite Equities

    By Meena Krishnamsetty - April 25, 2013 | Tickers: GM, NXY, SNY, TWTC, WAG

    Managed by the former head of Global Trading Strategies for Lehman Brothers, Realm Partners was started in 2009 by Robert Millard with $650 million. Before leaving Lehman as managing director in 2007, a year before Lehman filed for bankruptcy, Millard was given the highest pay package at the firm with $51.3 million, versus the $40 million paid to CEO Dick Fuld. Unfortunately, more than half of that was awarded more »

  • Investing in Potential Blockbusters

    By Shweta Dubey - April 19, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Investing in Potential Blockbusters

    By Shweta Dubey - April 6, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Investing in Potential Blockbusters

    By Shweta Dubey - April 6, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Want to do Blockbuster Investing?

    By Shweta Dubey - April 3, 2013 | Tickers: JNJ, NVS, SNY

    A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug. To create a blockbuster drug is a big achievement for any pharmaceutical company- both financially and operationally. In this article, I have discussed three drug manufacturers that are known for producing such drugs in the past. Let's see what future blockbusters they have in their portfolios:

    Sanofi (NYSE: SNY)

    The more »

  • Will This Successful Spin-off Mean More Spin-offs in the Industry?

    By Mike Thiessen - March 28, 2013 | Tickers: MRK, PFE, SNY, ZTS

    After a wildly successful IPO that raised over $2 billion, and valued the newly-created company at more than $12 billion, pharmaceutical giant Pfizer (NYSE: PFE) retains about 80% of the equity in its former animal drugs division Zoetis (NYSE: ZTS).

    Although Pfizer has not made any formal announcements of its plans for the remaining stake, it is widely expected to unwind a significant portion of its investment during the coming more »

  • These European Pharmaceuticals Show Promise

    By Robert Ciura - March 27, 2013 | Tickers: AZN, NVS, SNY

    Companies in the health care sector provide essentials to both customers and investors: namely their products and their dividends. It’s safe to assume that people need to take their medicines, no matter the prevailing economic climate.

    When most investors think of big pharma, they’d likely come up with the usual suspects. While the U.S-based health care giants are well-known to most investors and worthy of investor consideration more »

  • How to Profit From Increasing Obesity

    By Lee Samaha - March 19, 2013 | Tickers: COV, MCD, NVO, PEP, SNY

    Note: A previous version of this article incorrectly stated the effect of Novo Nordisk's type 2 diabetes treatment. The mistake has been corrected below.

    Funnily enough, I think that long term investors should be investing in the long term. In this article I’m going to discuss obesity, its prevalence and suggest some of the stocks that might be bought and avoided as a consequence.

    Obesity Prevalence

    Everyone loves more »

  • Will This Successful Spin-off Mean More Spin-offs in the Industry?

    By Mike Thiessen - March 18, 2013 | Tickers: MRK, PFE, SNY, ZTS

    After a wildly successful IPO that raised over $2 billion and valued the newly-created company at more than $12 billion, pharmaceutical giant Pfizer (NYSE: PFE) retains about 80 percent of the equity in its former animal drugs division Zoetis (NYSE: ZTS). Although Pfizer has not made any formal announcements of its plans for the remaining stake, it is widely expected to unwind a significant portion of its investment during the more »

  • Top # 10: International Companies (ADRs)

    By Rohit Gupta - March 18, 2013 | Tickers: BUD, AZN, GSK, NVS, NVO, SNY

    A list of Top 10 International companies, with ADRs (American Deposittory Receipts) listed in the US. While all large international brands – a synopsis of their unique competitive advantage and long term moat

    1. Anheuser-Busch (NYSE: BUD) : juggernaut in the global beer market with leadership position in four of the top five beer profit pools (United States, Canada, Brazil, and Mexico). Further, strength of ABI's focus brands (Budweiser, Stella Artois more »

  • Merrimack May Be Right For Your Portfolio

    By Terry Chrisomalis - March 18, 2013 | Tickers: CELG, MACK, SNY, THLD

    Merrimack Pharmaceuticals (NASDAQ: MACK) may be the perfect biotech company for your speculative portfolio. The company had its Initial Public Offering in March of 2012 and raised $100 million for its operations. The sale of the public offering was at $7 dollars a share, valuing the company at $647 million. Merrimack seems to have come to market at the right time, as it currently has eight drugs in it's more »

  • Pharmaceutical Winners And Losers In Early 2013

    By Bill Edson - March 7, 2013 | Tickers: LLY, JNJ, SNY, TEVA

    Once upon a time, pharmaceutical stocks were the darling of Wall Street. Today, many companies that research and develop new treatments are disappointing shareholders.

    Ultimately, that was the loss of those optimists. As value investors, we are not afraid of bad news as long as we get compensated by low valuations. Two stocks suffering bad news, Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ), are not cheap in light more »

  • Why I Am Long on Pfizer (And You Should Be Too)

    By Daniel Paterson - March 6, 2013 | Tickers: MRK, NVS, PFE, SNY

    Drug manufacturing juggernaut Pfizer (NYSE: PFE) has ripped out the gates in 2013, up 7% year to date. The big boost has come from a sizable 4Q 2012 earnings beat. Although Pfizer reported a decrease in revenue of 7%, they were still able to beat the analyst’s earnings per share estimates due to their ability to cut costs. Pfizer reported a 13% drop in costs of sales, a 7 more »

  • Page 1 of 6